Oxford Biomedica Statistics

Total Valuation

Oxford Biomedica has a market cap or net worth of GBP 451.83 million. The enterprise value is 485.69 million.

Market Cap	451.83M
Enterprise Value	485.69M

Important Dates

The next estimated earnings date is Tuesday, December 24, 2024.

Earnings Date	Dec 24, 2024
Ex-Dividend Date	n/a

Share Statistics

Oxford Biomedica has 105.94 million shares outstanding. The number of shares has increased by 4.65% in one year.

Current Share Class	n/a
Shares Outstanding	105.94M
Shares Change (YoY)	+4.65%
Shares Change (QoQ)	+8.91%
Owned by Insiders (%)	0.59%
Owned by Institutions (%)	51.96%
Float	69.70M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.42
PB Ratio	6.78
P/TBV Ratio	12.46
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-3.42
EV / Sales	4.99
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-6.74

Financial Position

The company has a current ratio of 2.35, with a Debt / Equity ratio of 1.55.

Current Ratio	2.35
Quick Ratio	1.99
Debt / Equity	1.55
Debt / EBITDA	n/a
Debt / FCF	-1.53
Interest Coverage	-6.55

Financial Efficiency

Return on equity (ROE) is -124.66% and return on invested capital (ROIC) is -16.61%.

Return on Equity (ROE)	-124.66%
Return on Assets (ROA)	-12.67%
Return on Capital (ROIC)	-16.61%
Revenue Per Employee	116,647
Profits Per Employee	-170,287
Employee Count	703
Asset Turnover	0.30
Inventory Turnover	4.09

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +112.44% in the last 52 weeks. The beta is 1.09, so Oxford Biomedica's price volatility has been similar to the market average.

Beta (5Y)	1.09
52-Week Price Change	+112.44%
50-Day Moving Average	417.07
200-Day Moving Average	336.30
Relative Strength Index (RSI)	48.27
Average Volume (20 Days)	146,050

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Oxford Biomedica had revenue of GBP 97.28 million and -142.02 million in losses. Loss per share was -1.41.

Revenue	97.28M
Gross Profit	35.74M
Operating Income	-65.49M
Pretax Income	-171.92M
Net Income	-142.02M
EBITDA	-55.94M
EBIT	-65.49M
Loss Per Share	-1.41

Full Income Statement

Balance Sheet

The company has 81.41 million in cash and 110.31 million in debt, giving a net cash position of -28.90 million or -0.27 per share.

Cash & Cash Equivalents	81.41M
Total Debt	110.31M
Net Cash	-28.90M
Net Cash Per Share	-0.27
Equity (Book Value)	71.22M
Book Value Per Share	0.63
Working Capital	79.73M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -62.30 million and capital expenditures -9.79 million, giving a free cash flow of -72.09 million.

Operating Cash Flow	-62.30M
Capital Expenditures	-9.79M
Free Cash Flow	-72.09M
FCF Per Share	-0.68

Full Cash Flow Statement

Margins

Gross margin is 36.74%, with operating and profit margins of -67.32% and -145.98%.

Gross Margin	36.74%
Operating Margin	-67.32%
Pretax Margin	-176.72%
Profit Margin	-145.98%
EBITDA Margin	-57.50%
EBIT Margin	-67.32%
FCF Margin	n/a

Dividends & Yields

Oxford Biomedica does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.65%
Shareholder Yield	-4.65%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

The last stock split was on May 30, 2018. It was a reverse split with a ratio of 0.02.

Last Split Date	May 30, 2018
Split Type	Reverse
Split Ratio	0.02

Scores

Oxford Biomedica has an Altman Z-Score of -1.44. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.44
Piotroski F-Score	n/a